APOB and Hypercholesterolemia: Carriers of an LDLR/APOB mutation were found to have higher baseline and post-treatment concentrations of total cholesterol (TC), LDL-C, and non-HDL-C, as compared to patients with polygenic hypercholesterolemia (Table 2).